HUP9900592A2 - Eljárás lamotrigint tartalmazó gyógyszerkészítmény tisztaságának vizsgálatára - Google Patents

Eljárás lamotrigint tartalmazó gyógyszerkészítmény tisztaságának vizsgálatára

Info

Publication number
HUP9900592A2
HUP9900592A2 HU9900592A HUP9900592A HUP9900592A2 HU P9900592 A2 HUP9900592 A2 HU P9900592A2 HU 9900592 A HU9900592 A HU 9900592A HU P9900592 A HUP9900592 A HU P9900592A HU P9900592 A2 HUP9900592 A2 HU P9900592A2
Authority
HU
Hungary
Prior art keywords
compound
purity
testing
pharmaceutical composition
composition containing
Prior art date
Application number
HU9900592A
Other languages
English (en)
Inventor
Lorraine Mary Edmeades
Nigel Arthur Griffith-Skinner
Derek Anthony Hill
Graham Thronton Hill
Terence William Packham
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9900592(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of HU9900592D0 publication Critical patent/HU9900592D0/hu
Publication of HUP9900592A2 publication Critical patent/HUP9900592A2/hu
Publication of HUP9900592A3 publication Critical patent/HUP9900592A3/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány tárgya eljárás lamőtrigin vagy lamőtrigint tartalmazógyógyszerkészítmény minta tisztaságának vagy bőmlással szembenistabilitásának vizsgálatára, amelyet úgy végeznek, hőgy megvizsgálják,hőgy a mintában jelen van-e a 3-aminő-6-(2,3-diklór-fenil)-1,2,4-triazin-5(4H)-őn (A vegyület) vagy az N-[5-aminő-6-(2,3-diklór-fenil)-1,2-4-triazin-3-il]-2,3-diklór-benzamnid (B vegyület). A (B) vegyületúj, a találmány a vegyületre és a vegyület előállítására szőlgálóeljárásra is vőnatkőzik. ŕ
HU9900592A 1998-06-10 1999-03-10 Process for testing the purity of pharmaceutical composition containing lamotrigine HUP9900592A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812413.4A GB9812413D0 (en) 1998-06-10 1998-06-10 Compound and its use

Publications (3)

Publication Number Publication Date
HU9900592D0 HU9900592D0 (en) 1999-04-28
HUP9900592A2 true HUP9900592A2 (hu) 2000-04-28
HUP9900592A3 HUP9900592A3 (en) 2002-04-29

Family

ID=10833464

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900592A HUP9900592A3 (en) 1998-06-10 1999-03-10 Process for testing the purity of pharmaceutical composition containing lamotrigine

Country Status (31)

Country Link
US (1) US6333198B1 (hu)
EP (2) EP0963980B1 (hu)
JP (1) JP2989189B1 (hu)
KR (1) KR100322354B1 (hu)
CN (2) CN1238454A (hu)
AP (3) AP0102286A0 (hu)
AR (1) AR014074A1 (hu)
AT (1) ATE218552T1 (hu)
AU (1) AU2031999A (hu)
BR (1) BR9900984A (hu)
CA (1) CA2265194C (hu)
DE (1) DE69901656T2 (hu)
DK (1) DK0963980T3 (hu)
EA (1) EA000666B1 (hu)
ES (1) ES2178342T3 (hu)
GB (1) GB9812413D0 (hu)
HR (1) HRP990074A2 (hu)
HU (1) HUP9900592A3 (hu)
ID (1) ID22957A (hu)
MA (1) MA24777A1 (hu)
NO (2) NO991151L (hu)
NZ (1) NZ334590A (hu)
PE (1) PE20000332A1 (hu)
PL (1) PL331870A1 (hu)
PT (1) PT963980E (hu)
SG (1) SG85628A1 (hu)
SI (1) SI0963980T1 (hu)
TR (1) TR199900520A2 (hu)
UY (1) UY25946A1 (hu)
YU (1) YU12399A (hu)
ZA (1) ZA991951B (hu)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
DE10085384B4 (de) * 2000-01-03 2006-06-14 Rpg Life Sciences Limited Ein Verfahren für die Herstellung von 6-(2,3-Dichlorphenyl)-1,2,4-triazin -3,5-diamin, im Allgemeinen bekannt als Lamotrigin
EP1309556B1 (en) 2000-12-29 2004-11-24 Pfizer Limited Amlodipine fumarate
BR0116554A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
MXPA03005885A (es) 2000-12-29 2005-04-19 Pfizer Ltd Procedimiento para fabricar maleato de amlodipina.
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
EP1309558A1 (en) 2000-12-29 2003-05-14 Synthon Licensing, Ltd. Aspartate derivative of amlodipine as calcium channel antagonist
GB2371862B (en) 2000-12-29 2004-07-14 Bioorg Bv Reference standards for determining the purity or stability of amlodipine maleate and processes therefor
EP1309557B9 (en) 2000-12-29 2006-11-15 Pfizer Limited Amlodipine hemimaleate
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
DE10134980C2 (de) 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
HU225667B1 (en) * 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
PT1689723E (pt) * 2003-12-02 2011-07-06 Teva Pharma Padrão referência para a caracterização de rosuvastatina
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005075427A2 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
CA2554572A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
MD2823G2 (ro) * 2004-02-12 2006-05-31 Институт Химии Академии Наук Молдовы Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
KR100815670B1 (ko) * 2004-04-21 2008-03-20 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트 나트륨을 제조하는 방법
JP2007532585A (ja) * 2004-04-26 2007-11-15 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸及びそのエステル誘導体の調製方法
CA2555454C (en) * 2004-04-27 2009-12-15 Sandor Molnar Mycophenolate mofetil impurity
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
CA2561015A1 (en) * 2004-06-28 2006-06-29 Teva Pharmaceutical Fine Chemicals S.R.L. Processes for the preparation of tomoxetine
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
DE602005020014D1 (de) * 2004-07-20 2010-04-29 Teva Gyogyszergyar Zartkoeruen Kristallines mycophenolat-natrium
CA2568629A1 (en) * 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
CN101068814A (zh) * 2004-09-04 2007-11-07 特瓦制药工业有限公司 分离的伐昔洛韦杂质，制备伐昔洛韦杂质的方法及其作为参比标准物的应用
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
WO2006037125A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
CA2582090A1 (en) * 2004-10-19 2006-04-27 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
WO2006076562A1 (en) * 2005-01-11 2006-07-20 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
TWI345562B (en) * 2005-02-22 2011-07-21 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
CA2602073A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
US7534900B2 (en) * 2005-03-14 2009-05-19 Teva Pharmaceutical Industries Ltd Process for the purification of duloxetine hydrochloride
EP1751085A1 (en) * 2005-04-05 2007-02-14 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
EP1866275A1 (en) * 2005-04-06 2007-12-19 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
MX2007012606A (es) * 2005-04-11 2008-01-11 Teva Pharma Proceso para elaborar (s)-pregabalina.
WO2006113425A1 (en) * 2005-04-14 2006-10-26 Teva Pharmaceutical Industries Ltd. Process for preparing quetiapine fumarate
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP1879852A1 (en) * 2005-05-10 2008-01-23 Teva Pharmaceutical Industries Ltd Pregabalin free of lactam and a process for preparation thereof
ES2372700T3 (es) * 2005-05-10 2012-01-25 Teva Pharmaceutical Industries Ltd Resolución óptica del ácido 3-carbamoilmetil-5-metil hexanoico.
MX2007000524A (es) * 2005-05-10 2007-03-28 Teva Pharma Metodo para la preparacion de pregabalina y sales de ella.
KR20070067077A (ko) * 2005-05-10 2007-06-27 테바 파마슈티컬 인더스트리즈 리미티드 이소부틸글루타르산을 함유하지 않는 프레가발린 및 이의제조 방법
TW200716512A (en) 2005-05-23 2007-05-01 Teva Pharma Processes for preparing cinacalcet hydrochloride crystal form I
CN101208312A (zh) * 2005-06-27 2008-06-25 西科尔公司 用于合成阿那曲唑及纯化一种阿那曲唑中间体的方法
US20070032660A1 (en) * 2005-06-27 2007-02-08 Alessandro Pontiroli Purification process for Anastrozole intermediate
US7812168B2 (en) * 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
BRPI0605917A2 (pt) * 2005-08-16 2009-05-26 Teva Pharma intermediário cristalino de rosuvastatina
US7563923B2 (en) * 2005-09-19 2009-07-21 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
WO2007067581A1 (en) 2005-12-05 2007-06-14 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphthol) thiophene, an impurity of duloxetine hydrochloride
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
CA2626715A1 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Processes for preparing darifenacin hydrobromide
CA2644819A1 (en) * 2006-03-27 2007-11-08 Teva Pharmaceutical Fine Chemicals S.R.L. Process for preparing memantine hydrochloride substantially free of impurities
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) * 2006-05-18 2006-06-28 Pliva Istrazivanje I Razvoj D Impurities of a pharmaceutical product
KR20080027880A (ko) * 2006-05-24 2008-03-28 테바 파마슈티컬 인더스트리즈 리미티드 Ｒ-(+)-3-(카바모일메틸)-5-메틸헥산산 및 이의 염의 제조방법
EP1913147A2 (en) * 2006-05-31 2008-04-23 Teva Pharmaceutical Industries Ltd The use of enzymatic resolution for the preparation of intermediates of pregabalin
US20080015385A1 (en) * 2006-05-31 2008-01-17 Lilach Hedvati Preparation of (S)-pregabalin-nitrile
ES2339297T3 (es) * 2006-06-29 2010-05-18 Ivax Pharmaceuticals S.R.O. Regulacion de la produccion de metabolitos acidos.
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CN101506178A (zh) * 2006-08-14 2009-08-12 隆沙有限公司 制备拉莫三嗪的方法
WO2008106179A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Intermediates and processes for the synthesis of ramelteon
US8097754B2 (en) * 2007-03-22 2012-01-17 Teva Pharmaceutical Industries Ltd. Synthesis of (S)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
MX2008015797A (es) * 2007-04-11 2009-03-06 Teva Gyogyszergyar Zartkoeruen Metodo para reducir el nivel de impurezas en la fermentacion del acido micofenolico.
EP2069320A2 (en) * 2007-05-31 2009-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2009046309A2 (en) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
EP2537847A1 (en) * 2007-10-23 2012-12-26 Teva Pharmaceutical Industries, Ltd. Polymorphs of dasatinib and process for preparation thereof
US20090281176A1 (en) * 2007-11-01 2009-11-12 Vinod Kumar Kansal Process for the synthesis of ramelteon and its intermediates
WO2009061513A1 (en) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Crystalline forms of lamotrigine
CA2717580A1 (en) * 2008-03-06 2009-12-17 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
EP2297090A1 (en) * 2008-06-23 2011-03-23 Teva Pharmaceutical Industries Ltd. Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010045565A1 (en) * 2008-10-16 2010-04-22 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
CA2795023A1 (en) * 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) * 2012-08-20 2012-11-07 三金集团湖南三金制药有限责任公司 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
CN110467560A (zh) 2018-05-09 2019-11-19 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) * 2021-04-20 2023-12-22 三金集团湖南三金制药有限责任公司 高效液相色谱分析拉莫三嗪的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS234018B2 (en) 1979-06-01 1985-03-14 Wellcome Found Method of 3,5-diammino-6-1,2,4-triazine derivatives making
JPS5625170A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
RU2145602C1 (ru) * 1994-12-30 2000-02-20 Де Вэллкам Фаундейшн Лимитед Способы получения ламотриджина, промежуточные соединения и способ получения фармацевтической композиции
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation

Also Published As

Publication number Publication date
AP9901481A0 (en) 1999-03-31
JP2989189B1 (ja) 1999-12-13
JP2000009714A (ja) 2000-01-14
NO991151D0 (no) 1999-03-10
CN1238454A (zh) 1999-12-15
YU12399A (sh) 2002-08-12
EA199900159A1 (ru) 1999-12-29
DE69901656D1 (de) 2002-07-11
PT963980E (pt) 2002-10-31
DK0963980T3 (da) 2002-09-16
BR9900984A (pt) 2000-05-02
SG85628A1 (en) 2002-01-15
GB9812413D0 (en) 1998-08-05
HU9900592D0 (en) 1999-04-28
CN1306210A (zh) 2001-08-01
KR20000005611A (ko) 2000-01-25
US6333198B1 (en) 2001-12-25
AR014074A1 (es) 2001-01-31
CA2265194C (en) 2000-10-10
MA24777A1 (fr) 1999-10-01
ZA991951B (en) 1999-08-16
ATE218552T1 (de) 2002-06-15
AU2031999A (en) 2000-01-06
PL331870A1 (en) 1999-12-20
HUP9900592A3 (en) 2002-04-29
SI0963980T1 (en) 2002-12-31
UY25946A1 (es) 2000-12-29
EA000666B1 (ru) 2000-02-28
NO20032753D0 (no) 2003-06-17
AP0102286A0 (en) 2000-09-10
EP0963980A3 (en) 2000-05-31
AP2001002286A0 (en) 2001-12-31
NO991151L (no) 1999-12-13
ES2178342T3 (es) 2002-12-16
NO20032753L (no) 1999-12-13
ID22957A (id) 1999-12-23
TR199900520A3 (tr) 2000-01-21
EP0963980B1 (en) 2002-06-05
PE20000332A1 (es) 2000-04-10
EP1170588A1 (en) 2002-01-09
NZ334590A (en) 2000-07-28
KR100322354B1 (ko) 2002-02-07
DE69901656T2 (de) 2003-01-30
TR199900520A2 (en) 2000-01-21
EP0963980A2 (en) 1999-12-15
HRP990074A2 (en) 2000-10-31

Similar Documents

Publication Publication Date Title
HUP9900592A2 (hu) Eljárás lamotrigint tartalmazó gyógyszerkészítmény tisztaságának vizsgálatára
PL306084A1 (en) Novel compound and method of obtaining them as well as pharmaceutic agent containing such compounds
IL96407A0 (en) Diazine derivatives
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DK166278C (da) Triazinsalt, fremgangsmaade til dets fremstilling og farmaceutisk komposition indeholdende saltet
MX9203417A (es) Compuestos de diarilo antiateroescleroticos.
ES2036926A1 (es) "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina".
HUP0105308A2 (hu) Eletriptán-hidrobromid-monohidrát, eljárás az előállítására és a vegyületet tartalmazó gyógyszerkészítmények
HUP9701660A2 (hu) 10,13,15-trioxa-triciklo[9.2.1.1. 9.6]pentadekanon-származékok, eljárás ezek előállítására, és az e vegyületeket tartalmazó gyógyászati készítmények
HUP0402037A2 (hu) 2-Amino-tiazolin-származékok alkalmazása indukálható NO-szintetáz inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
IL104775A0 (en) Pharmaceutical compositions containing triazine derivatives
HUP0104029A2 (hu) A 3-(2,4-diklór-benzil)-2-metil-N-(pentil-szulfonil)-3H-benzimidazol-5-karboxamid új kristályformái és azokat hatóanyagként tartalmazó gyógyszerkészítmények
HUP9900263A2 (hu) 11-Acetil-12,13-dioxabiciklo[8.2.1]tridecenon-származékok, eljárás ezek előállítására és az e vegyületeket tartalmazó gyógyászati készítmények
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
HUP0104213A2 (hu) Vankoreszmicin, eljárás előállítására és gyógyszerként történő alkalmazása
HUP0203593A2 (hu) Amikomicin, eljárás előállítására és gyógyszerként történő alkalmazása
ES2058761T3 (es) Proceso para la preparacion de derivados de dibenzodioxazecina y dibenzodioxaazacicloundecina.
IT7819422A0 (it) Procedimento per la produzione di tetraidro-1,2,4-triazine 3-sostituite e composti di questo tipo